J&J hands Tra­con two drugs, out­lines buy­back; Zymeworks does a cross-li­cens­ing deal with Dai­ichi Sankyo

Typ­i­cal­ly we see Big Phar­mas in-li­cens­ing ex­per­i­men­tal drugs from small biotechs. But in a re­verse of those roles, San Diego-based Tra­con Phar­ma­ceu­ti­cals bagged a cou­ple …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER